omeprazole has been researched along with Precordial Catch in 37 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To estimate the effect of double omeprazole dose on the course of angina pectoris and treadmill stress test in patients with coronary artery disease (CAD), using double-blind, crossover randomised, placebo-controlled study design." | 9.13 | The effect of double dose of omeprazole on the course of angina pectoris and treadmill stress test in patients with coronary artery disease--a randomised, double-blind, placebo controlled, crossover trial. ( Budzyński, J; Fabisiak, J; Kłopocka, M; Majer, M; Pulkowski, G; Suppan, K; Swiatkowski, M, 2008) |
| "To determine the clinical value of an empirical trial of high-dose lansoprazole in detecting patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 9.11 | The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial. ( Bautista, J; Briseno, M; Cui, H; Fass, R; Fullerton, H, 2004) |
| "Therapeutic trials with high-dose lansoprazole and omeprazole have been shown to be sensitive clinical tools for diagnosing patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 9.11 | The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. ( Cui, H; Dickman, R; Emmons, S; Esquivel, RF; Fass, R; Hernández, D; Sewell, J, 2005) |
| "Seventy-one percent of patients in the omeprazole arm reported improved chest pain, whereas only 18% in the placebo arm did." | 9.10 | Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. ( Arezo, S; Crofts, T; DeCosta, G; Everett, S; Gennings, C; Jesse, R; Pandak, WM; Siuta, M; Zfass, A, 2002) |
| "Treatment with lansoprazole is a useful test in diagnosing endoscopy-negative gastro-oesophageal reflux disease in Chinese patients with non-cardiac chest pain." | 9.10 | Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. ( Chan, CK; Chen, WH; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Lau, CP; Wong, BC; Wong, NY; Wong, WM; Xia, HH, 2003) |
| " The aim of this study was to evaluate the efficacy of the omeprazole test (OT) in diagnosing gastroesophageal reflux (GERD) in patients with NCCP and estimate the potential cost savings of this strategy compared with conventional diagnostic evaluations." | 9.08 | The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. ( Camargo, E; Fass, R; Fennerty, MB; Gralnek, IM; Johnson, C; Ofman, JJ; Sampliner, RE, 1998) |
| "Among patients with noncardiac chest pain, diagnostic strategies that begin with the omeprazole test result in reduced costs, improved diagnostic certainty, and a greater proportion of symptom-free patients at 1 year than do traditional strategies that begin with invasive diagnostic tests." | 7.70 | The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. ( Fass, R; Fennerty, MB; Gralnek, IM; Ofman, JJ; Udani, J, 1999) |
| "Gastroesophageal reflux is frequently found in patients with chest pain despite normal coronary anatomy, but little data on the effect of specific medication exist." | 6.69 | Effect of omeprazole in patients with chest pain and normal coronary anatomy: initial experience. ( Anggiansah, A; Chambers, J; Cooke, R; Owen, W, 1998) |
| "Gastroesophageal reflux (GER) occurs in 22-66% of patients with noncardiac chest pain (NCCP)." | 6.68 | Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. ( Achem, SR; Burton, L; Castell, DO; Kolts, BE; MacMath, T; Mohr, D; Richter, J, 1997) |
| "Drug-induced esophagitis is an uncommon diagnosis in the pediatric population." | 5.56 | L-arginine-induced esophagitis, report of six cases. ( Casaubón-Garcín, PR; Ferreiro-Marin, A; González-Cruz, MÁ; Parra, PR, 2020) |
| "To estimate the effect of double omeprazole dose on the course of angina pectoris and treadmill stress test in patients with coronary artery disease (CAD), using double-blind, crossover randomised, placebo-controlled study design." | 5.13 | The effect of double dose of omeprazole on the course of angina pectoris and treadmill stress test in patients with coronary artery disease--a randomised, double-blind, placebo controlled, crossover trial. ( Budzyński, J; Fabisiak, J; Kłopocka, M; Majer, M; Pulkowski, G; Suppan, K; Swiatkowski, M, 2008) |
| "To determine the clinical value of an empirical trial of high-dose lansoprazole in detecting patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 5.11 | The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial. ( Bautista, J; Briseno, M; Cui, H; Fass, R; Fullerton, H, 2004) |
| "Therapeutic trials with high-dose lansoprazole and omeprazole have been shown to be sensitive clinical tools for diagnosing patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 5.11 | The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. ( Cui, H; Dickman, R; Emmons, S; Esquivel, RF; Fass, R; Hernández, D; Sewell, J, 2005) |
| "Seventy-one percent of patients in the omeprazole arm reported improved chest pain, whereas only 18% in the placebo arm did." | 5.10 | Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. ( Arezo, S; Crofts, T; DeCosta, G; Everett, S; Gennings, C; Jesse, R; Pandak, WM; Siuta, M; Zfass, A, 2002) |
| "Treatment with lansoprazole is a useful test in diagnosing endoscopy-negative gastro-oesophageal reflux disease in Chinese patients with non-cardiac chest pain." | 5.10 | Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. ( Chan, CK; Chen, WH; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Lau, CP; Wong, BC; Wong, NY; Wong, WM; Xia, HH, 2003) |
| "The research was aimed at evaluating the efficiency of the inhibitor of the Rabeprazole (Pariet) proton pump in the therapy of the gastroesophageal reflux disease (GERD) with extra esophagus manifestations, and the presence of pains in the chest not caused by cardiac diseases." | 5.10 | [Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease]. ( Danilin, MS; Kucheriavyĭ, IuA; Maev, IV, 2003) |
| " The aim of this study was to evaluate the efficacy of the omeprazole test (OT) in diagnosing gastroesophageal reflux (GERD) in patients with NCCP and estimate the potential cost savings of this strategy compared with conventional diagnostic evaluations." | 5.08 | The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. ( Camargo, E; Fass, R; Fennerty, MB; Gralnek, IM; Johnson, C; Ofman, JJ; Sampliner, RE, 1998) |
| "Among patients with noncardiac chest pain, diagnostic strategies that begin with the omeprazole test result in reduced costs, improved diagnostic certainty, and a greater proportion of symptom-free patients at 1 year than do traditional strategies that begin with invasive diagnostic tests." | 3.70 | The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. ( Fass, R; Fennerty, MB; Gralnek, IM; Ofman, JJ; Udani, J, 1999) |
| "Gastroesophageal reflux is frequently found in patients with chest pain despite normal coronary anatomy, but little data on the effect of specific medication exist." | 2.69 | Effect of omeprazole in patients with chest pain and normal coronary anatomy: initial experience. ( Anggiansah, A; Chambers, J; Cooke, R; Owen, W, 1998) |
| "Gastroesophageal reflux disease (GERD) accounts for up to 60% of patients with noncardiac chest pain (NCCP)." | 2.69 | Correlation of ambulatory 24-hour esophageal pH monitoring results with symptom improvement in patients with noncardiac chest pain due to gastroesophageal reflux disease. ( Camargo, L; Fass, R; Fennerty, MB; Johnson, C; Sampliner, RE, 1999) |
| "Gastroesophageal reflux (GER) occurs in 22-66% of patients with noncardiac chest pain (NCCP)." | 2.68 | Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. ( Achem, SR; Burton, L; Castell, DO; Kolts, BE; MacMath, T; Mohr, D; Richter, J, 1997) |
| "Gastroesophageal reflux was found in 13 of 20 patients (65%) who underwent pH studies, and endoscopy detected one patient with erosive esophagitis." | 2.67 | Chest pain associated with nutcracker esophagus: a preliminary study of the role of gastroesophageal reflux. ( Achem, SR; Burton, L; Kolts, BE; Richter, JE; Wears, R, 1993) |
| "Heartburn was a poor predictor of whether patients with chest pain were GORD-positive or GORD-negative by objective testing." | 2.47 | Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. ( Howden, CW; Hughes, N; Kahrilas, PJ, 2011) |
| "Gastroesophageal reflux disease is the most common esophageal abnormality associated with unexplained chest pain and may be identified by an aggressive trial of anti-reflux therapy or an abnormal prolonged ambulatory pH monitoring study." | 2.41 | Approach to the patient with unexplained chest pain. ( Katz, PO, 2001) |
| "Occult gastroesophageal reflux disease (GERD) is more common than motor disorders and is found in 30% to 40% of these patients; a subset has hypersensitivity, with a normal pH profile." | 2.41 | Noncardiac chest pain. ( Botoman, VA, 2002) |
| "Noncardiac chest pain is a common but important clinical challenge with respect to diagnostic strategy as well as therapeutic intervention." | 2.39 | Pathophysiology and management of noncardiac chest pain. ( Joseph, AS; Minocha, A, 1995) |
| "Drug-induced esophagitis is an uncommon diagnosis in the pediatric population." | 1.56 | L-arginine-induced esophagitis, report of six cases. ( Casaubón-Garcín, PR; Ferreiro-Marin, A; González-Cruz, MÁ; Parra, PR, 2020) |
| "ECG showed right bundle branch block pattern and T wave inversion in leads V1 to V3, although these changes were present in old ECGs." | 1.46 | Oesophageal ischaemia: an uncommon cause of chest pain. ( Algieder, A; Rameh, B; Sasegbon, A, 2017) |
| "Chest pain is a common cause for referral to emergency departments." | 1.42 | A jackhammer in the gullet: high amplitude oesophageal contractions as a cause of atypical chest pain. ( Anggiansah, A; Goel, R; Wilkinson, M; Wong, T, 2015) |
| "Although Boerhaave syndrome is generally considered to have poor prognosis, conservative therapy may be effective in select cases with early detection of the perforation." | 1.33 | Boerhaave syndrome treated conservatively following early endoscopic diagnosis: a case report. ( Katsuno, A; Makino, H; Matsuda, A; Matsutani, T; Miyashita, M; Nomura, T; Sasajima, K; Sasaki, J; Tajiri, T, 2006) |
| "In 14 patients with chest pain and GERD and 8 healthy volunteers, electrical pain thresholds (PT) were recorded from the upper esophagus before, and then repeatedly for 90 min after either hydrochloric acid (0." | 1.32 | Patients with chest pain and occult gastroesophageal reflux demonstrate visceral pain hypersensitivity which may be partially responsive to acid suppression. ( Aziz, Q; Hobson, AR; Millane, T; Sarkar, S; Thompson, DG; Woolf, CJ, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.70) | 18.7374 |
| 1990's | 13 (35.14) | 18.2507 |
| 2000's | 18 (48.65) | 29.6817 |
| 2010's | 4 (10.81) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Parra, PR | 1 |
| González-Cruz, MÁ | 1 |
| Ferreiro-Marin, A | 1 |
| Casaubón-Garcín, PR | 1 |
| Sasegbon, A | 1 |
| Algieder, A | 1 |
| Rameh, B | 1 |
| Thompson, MH | 1 |
| Corbett, GD | 1 |
| Cherian, A | 1 |
| Nicol, ED | 1 |
| Goel, R | 1 |
| Anggiansah, A | 2 |
| Wong, T | 1 |
| Wilkinson, M | 1 |
| Achem, SR | 4 |
| Kahrilas, PJ | 1 |
| Hughes, N | 1 |
| Howden, CW | 1 |
| Pandak, WM | 1 |
| Arezo, S | 1 |
| Everett, S | 1 |
| Jesse, R | 1 |
| DeCosta, G | 1 |
| Crofts, T | 1 |
| Gennings, C | 1 |
| Siuta, M | 1 |
| Zfass, A | 1 |
| Xia, HH | 1 |
| Lai, KC | 1 |
| Lam, SK | 1 |
| Hu, WH | 1 |
| Wong, NY | 1 |
| Hui, WM | 1 |
| Lau, CP | 1 |
| Chen, WH | 1 |
| Chan, CK | 1 |
| Wong, WM | 1 |
| Wong, BC | 1 |
| Maev, IV | 2 |
| Kucheriavyĭ, IuA | 1 |
| Danilin, MS | 1 |
| Borjesson, M | 1 |
| Rolny, P | 1 |
| Mannheimer, C | 1 |
| Pilhall, M | 1 |
| Bautista, J | 1 |
| Fullerton, H | 1 |
| Briseno, M | 1 |
| Cui, H | 2 |
| Fass, R | 6 |
| Sarkar, S | 1 |
| Thompson, DG | 1 |
| Woolf, CJ | 1 |
| Hobson, AR | 1 |
| Millane, T | 1 |
| Aziz, Q | 1 |
| Füessl, HS | 1 |
| Dickman, R | 1 |
| Emmons, S | 1 |
| Sewell, J | 1 |
| Hernández, D | 1 |
| Esquivel, RF | 1 |
| Matsuda, A | 1 |
| Miyashita, M | 1 |
| Sasajima, K | 1 |
| Nomura, T | 1 |
| Makino, H | 1 |
| Matsutani, T | 1 |
| Katsuno, A | 1 |
| Sasaki, J | 1 |
| Tajiri, T | 1 |
| Tsai, SH | 1 |
| Chang, WC | 1 |
| Chu, SJ | 1 |
| Wu, CP | 1 |
| Iurenev, GL | 1 |
| Burkov, SG | 1 |
| V'iuchnova, ES | 1 |
| Budzyński, J | 1 |
| Kłopocka, M | 1 |
| Pulkowski, G | 1 |
| Suppan, K | 1 |
| Fabisiak, J | 1 |
| Majer, M | 1 |
| Swiatkowski, M | 1 |
| Minocha, A | 1 |
| Joseph, AS | 1 |
| Thumshirn, M | 1 |
| Stahl, WG | 1 |
| Beton, RR | 1 |
| Johnson, CS | 1 |
| Brown, CL | 1 |
| Waring, JP | 1 |
| Kolts, BE | 2 |
| Wears, R | 1 |
| Burton, L | 2 |
| Richter, JE | 2 |
| Adamek, RJ | 1 |
| Wegener, M | 1 |
| Wienbeck, M | 1 |
| Pulte, T | 1 |
| MacMath, T | 1 |
| Richter, J | 1 |
| Mohr, D | 1 |
| Castell, DO | 2 |
| Fennerty, MB | 3 |
| Ofman, JJ | 2 |
| Gralnek, IM | 2 |
| Johnson, C | 2 |
| Camargo, E | 1 |
| Sampliner, RE | 2 |
| Katz, PO | 2 |
| Chambers, J | 1 |
| Cooke, R | 1 |
| Owen, W | 1 |
| Friedel, D | 1 |
| Ozick, LA | 1 |
| Camargo, L | 1 |
| Udani, J | 1 |
| DeVault, KR | 1 |
| Botoman, VA | 1 |
| Bory, M | 1 |
| Dupin, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Non-cardiac Chest Pain Evaluation and Treatment Study (CARPA) - Part 2: Treatment Study[NCT00462241] | 115 participants (Actual) | Interventional | 2006-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for omeprazole and Precordial Catch
| Article | Year |
|---|---|
Treatment of non-cardiac chest pain.
Topics: Anti-Ulcer Agents; Botulinum Toxins, Type A; Calcium Channel Blockers; Chest Pain; Diltiazem; Enzyme | 2008 |
Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Esophagus; Gastroesophageal Reflux; Heartburn; | 2011 |
Pathophysiology and management of noncardiac chest pain.
Topics: Arousal; Chest Pain; Diagnosis, Differential; Esophageal Motility Disorders; Esophagogastric Junctio | 1995 |
Empirical trials in treatment of gastroesophageal reflux disease.
Topics: Chest Pain; Clinical Trials as Topic; Cost-Benefit Analysis; Diagnosis, Differential; Enzyme Inhibit | 2000 |
Recent developments in chest pain of undetermined origin.
Topics: Angina Pectoris; Anti-Ulcer Agents; Chest Pain; Diagnosis, Differential; Esophageal Diseases; Humans | 2000 |
Approach to the patient with unexplained chest pain.
Topics: Adult; Algorithms; Anti-Ulcer Agents; Chest Pain; Diagnosis, Differential; Esophagus; Gastroesophage | 2001 |
Noncardiac chest pain.
Topics: Algorithms; Anti-Anxiety Agents; Anti-Ulcer Agents; Chest Pain; Diagnosis, Differential; Esophagus; | 2002 |
13 trials available for omeprazole and Precordial Catch
| Article | Year |
|---|---|
Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring.
Topics: Adult; Aged; Anti-Ulcer Agents; Chest Pain; Cross-Over Studies; Diagnosis, Differential; Dose-Respon | 2002 |
Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Chest Pain; Female; Gastroe | 2003 |
[Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Chest Pain; Enzyme Inhibitors; Femal | 2003 |
Nutcracker oesophagus: a double-blind, placebo-controlled, cross-over study of the effects of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Anti-Ulcer Agents | 2003 |
The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Chest Pa | 2004 |
The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Chest Pain; | 2005 |
[Rabeprazole test and comparison of the effectiveness of course treatment with rabeprazole in patients with gastroesophageal reflux disease and non-coronary chest pain].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Chest Pain; Female; Gastroe | 2007 |
The effect of double dose of omeprazole on the course of angina pectoris and treadmill stress test in patients with coronary artery disease--a randomised, double-blind, placebo controlled, crossover trial.
Topics: Analysis of Variance; Angina Pectoris; Anti-Ulcer Agents; Chest Pain; Coronary Disease; Cross-Over S | 2008 |
Chest pain associated with nutcracker esophagus: a preliminary study of the role of gastroesophageal reflux.
Topics: Adult; Aged; Chest Pain; Esophageal Motility Disorders; Esophagoscopy; Esophagus; Female; Gastric Ac | 1993 |
Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux.
Topics: Chest Pain; Double-Blind Method; Esophagus; Female; Follow-Up Studies; Gastric Acidity Determination | 1997 |
The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain.
Topics: Adult; Aged; Aged, 80 and over; Chest Pain; Double-Blind Method; Enzyme Inhibitors; Female; Gastroes | 1998 |
Effect of omeprazole in patients with chest pain and normal coronary anatomy: initial experience.
Topics: Adult; Chest Pain; Coronary Angiography; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; | 1998 |
Correlation of ambulatory 24-hour esophageal pH monitoring results with symptom improvement in patients with noncardiac chest pain due to gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Chest Pain; Esophagus; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Conc | 1999 |
17 other studies available for omeprazole and Precordial Catch
| Article | Year |
|---|---|
L-arginine-induced esophagitis, report of six cases.
Topics: Adolescent; Arginine; Chest Pain; Child; Deglutition Disorders; Esophageal Mucosa; Esophagitis; Fema | 2020 |
Oesophageal ischaemia: an uncommon cause of chest pain.
Topics: Aged; Atrial Fibrillation; Bundle-Branch Block; Chest Pain; Computed Tomography Angiography; Endosco | 2017 |
A massive occult pericardial effusion in an athletic young male.
Topics: Adult; Anti-Ulcer Agents; Chest Pain; Colchicine; Delayed Diagnosis; Glucocorticoids; Gout Suppressa | 2013 |
A jackhammer in the gullet: high amplitude oesophageal contractions as a cause of atypical chest pain.
Topics: Anti-Ulcer Agents; Chest Pain; Esophageal Motility Disorders; Gastroesophageal Reflux; Humans; Male; | 2015 |
[Proton pump inhibition: more than only reflux therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Chest Pain; Clopidogrel; Comorbi | 2008 |
Patients with chest pain and occult gastroesophageal reflux demonstrate visceral pain hypersensitivity which may be partially responsive to acid suppression.
Topics: Acids; Adult; Chest Pain; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Pa | 2004 |
[The best strategies against reflux disease. Acid stomach and the sequelae].
Topics: Anti-Ulcer Agents; Barrett Esophagus; Chest Pain; Esophagitis; Gastroesophageal Reflux; Helicobacter | 2004 |
Boerhaave syndrome treated conservatively following early endoscopic diagnosis: a case report.
Topics: Adult; Anti-Bacterial Agents; Chest Pain; Combined Modality Therapy; Endoscopy, Gastrointestinal; En | 2006 |
Chest pain during triple therapy for duodenal ulcer.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Chest Pain; Clarithromycin; | 2007 |
[A case from practice (316). Hiccups in grade I reflux esophagitis and hiatal hernia. Suspected coronary heart disease in NYHA II angina pectoris].
Topics: Aged; Aged, 80 and over; Angina Pectoris; Chest Pain; Coronary Disease; Diagnosis, Differential; Eso | 1995 |
Diagnosis and treatment of patients with gastroesophageal reflux and noncardiac chest pain.
Topics: Adult; Aged; Aged, 80 and over; Barium Sulfate; Chest Pain; Diagnosis, Differential; Esophagoscopy; | 1994 |
Esophageal motility disorders and their coexistence with pathologic acid reflux in patients with noncardiac chest pain.
Topics: Adult; Aged; Analysis of Variance; Anti-Ulcer Agents; Chest Pain; Diagnosis, Differential; Esophagea | 1995 |
The acid suppression test for unexplained chest pain.
Topics: Chest Pain; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Omeprazo | 1998 |
High-dose omeprazole in patients with noncardiac chest pain.
Topics: Anti-Ulcer Agents; Chest Pain; Gastroesophageal Reflux; Humans; Omeprazole | 1999 |
The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain.
Topics: Anti-Ulcer Agents; Chest Pain; Cost-Benefit Analysis; Decision Trees; Diagnosis, Differential; Esoph | 1999 |
Cost-effectiveness of testing for gastroesophageal reflux disease: what do patients, physicians, and health insurers want?
Topics: Anti-Ulcer Agents; Chest Pain; Cost-Benefit Analysis; Diagnosis, Differential; Esophagoscopy; Gastro | 1999 |
[Angina-like chest pain of esophageal origin].
Topics: Catheterization; Chest Pain; Esophageal Diseases; Humans; Hydrochloric Acid; Hydrogen-Ion Concentrat | 1989 |